Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00518297 | DDI HV (ATV - Merck) | PHASE1 | COMPLETED | 22 | — | — | Aug 1, 2007 | Dec 1, 2007 | Feb 4, 2010 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | - |
| 2 | ACTIVE_COMPARATOR | - |
| 3 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Raltegravir | DRUG | Tablet, Oral, 400 mg, twice daily for 5 Days |
| Atazanavir | DRUG | Capsule, Oral, 300 mg, twice daily for 7 Days |
| Atazanavir + Raltegravir | DRUG | Capsule/Tablet, Oral, 300/400, twice daily for 14 Days |
Inclusion Criteria: * Healthy male and female subjects between the ages of 18 to 45 years old with a body mass index (BMI) of 18 to 32 kg/m² * Prior to enrollment, subjects must have physical and laboratory test findings within normal limits, and women of childbearing potential (WOCBP) must have a ...